Canntab Therapeutics Limited

Recent News

  • Canntab Announces Cancellation of Options and Issuance of Warrants

    Toronto, Ontario--(Newsfile Corp. - March 3, 2020) - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that the Board of Directors passed a resolution to issue 1,300,000 warrants ("Warrants")...

    2020-03-03 7:20 PM ET
  • FSD Pharma Receives Cannabis Sales License from Health Canada

    Toronto, Ontario--(Newsfile Corp. - April 22, 2019) - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), announced today that its wholly-owned subsidiary FV Pharma Inc. has received its Sale for Medical Purposes license to sell cannabis under the Cannabis Act (Canada). The license went...

    2019-04-22 8:30 AM ET
  • Canntab Files Application to Become Licensed Producer

    Toronto, Ontario--(Newsfile Corp. - October 18, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") a leader in the development of precision oral dose cannabis tablets and capsules, is pleased to announce that it has filed an application to become a Licensed Producer under the Access...

    2018-10-18 7:43 AM ET
  • Canntab Enters LOI for Bi-Lateral Sales & Distribution and Cannabis Oil Supply

    Toronto, Ontario--(Newsfile Corp. - October 1, 2018) - Canntab Therapeutics Limited (CSE: PILL) (FSE: TBF1) ("Canntab" or the "Company"), today announced the completion of a non-binding Letter of Intent (the "LOI") with NewCanna S.A.S of Bogota, Colombia ("NewCanna") for the establishment of a significant bi-lateral relationship for the sale...

    2018-10-01 12:25 AM ET
  • FSD Pharma Receives First Delivery of Canntab Equipment with a Capacity to Manufacture Approx. 1,500,000 Tablets per Day

    Toronto, Ontario--(Newsfile Corp. - September 25, 2018) - FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FSE: 0K9) ("FSD Pharma" or the "Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that the...

    2018-09-25 9:00 AM ET
  • Canntab Added to CSE Composite Index

    Toronto, Ontario--(Newsfile Corp. - September 24, 2018) - Canntab Therapeutics Limited (CSE: PILL) (FSE: TBF1) ("Canntab" or the "Company"), is pleased to inform investors that effective September 21, 2018 the Company has been added to the Composite Index of the Canadian Securities Exchange as part of the CSE's quarterly rebalancing.Based...

    2018-09-24 9:34 AM ET
  • Canntab Sets New All-Time High Trading Prices and Volume

    Toronto, Ontario--(Newsfile Corp. - September 20, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company"), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that the Company's common shares ("Common Shares") yesterday reached new all-time daily high and closing prices...

    2018-09-20 9:00 AM ET
  • Canntab Exceeds All-Time High Trading Prices and Grants Options

    Toronto, Ontario--(Newsfile Corp. - September 19, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company"), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that the Company's common shares ("Common Shares") yesterday reached new all-time daily high and closing prices...

    2018-09-19 9:00 AM ET